The Full Wiki

CD135: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Fms-related tyrosine kinase 3
Symbols FLT3; STK1; CD135; FLK2
External IDs OMIM136351 MGI95559 HomoloGene3040 GeneCards: FLT3 Gene
RNA expression pattern
PBB GE FLT3 206674 at tn.png
More reference expression data
Species Human Mouse
Entrez 2322 14255
Ensembl ENSG00000122025 ENSMUSG00000042817
UniProt P36888 Q2VPD1
RefSeq (mRNA) NM_004119 NM_010229
RefSeq (protein) NP_004110 NP_034359
Location (UCSC) Chr 13:
27.48 - 27.57 Mb
Chr 5:
147.64 - 147.71 Mb
PubMed search [1] [2]

CD135 is a cytokine receptor expressed on the surface of hematopoietic progenitor cells.



fms-like tyrosine kinase receptor-3 (Flt3), fetal liver kinase-2 (Flk2)

Cell Surface Marker

Cluster of differentiation (CD) molecules are markers on the cell surface, as recognized by specific sets of antibodies, used to identify the cell type, stage of differentiation and activity of a cell. CD135 is an important cell surface marker used to identify certain types of hematopoietic (blood) progenitors in the bone marrow. Specifically, multipotent progenitors (MPP) and common lymphoid progenitors (CLP) express high surface levels of CD135. This marker is therefore used to differentiate hematopoietic stem cells (HSC), which are CD135 negative, from MPPs, which are CD135 positive.


CD135 is the receptor for the cytokine Flt3 ligand (Flt3L).


CD135 is a receptor tyrosine kinase type III. When this receptor binds to Flt3L it forms a dimer with itself (homodimer) which activates signaling through second messengers. Signaling through CD135 plays a role in cell survival, proliferation, and differentiation. CD135 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells (myeloid development).

Role in cancer

CD135 is a proto-oncogene, meaning that mutations of this protein can lead to cancer[1]. Mutations of the Flt3 receptor can lead to the development of leukemia, a cancer of bone marrow hematopoietic progenitors. Internal tandem duplications of Flt3 (Flt3-ITD) are the most common mutations associated with acute myelogenous leukemia (AML) and are a poor prognostic indicator.

AC220 is in phase II clinical trials for AML patients with FLT3 mutations.[2][3]

See also


  1. ^ FLT3 (FMS-like tyrosine kinase 3)
  2. ^ "Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (ACE)"
  3. ^ "Astellas Pays $40M Up Front to Develop Ambit’s FLT3 Kinase Inhibitors"

Further reading

External links



Got something to say? Make a comment.
Your name
Your email address